Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma in High Risk Children with COVID-19
NCT04377672Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- May 2020
- Primary completion
- Sep 2021
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by Johns Hopkins University. Primary endpoint: Safety of Treatment With High-titer Anti-SARS-CoV-2 Plasma as Assessed by Adverse Events at 28 days. Started May 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04377672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377672.